Abstract
A total of 114 patients with bronchogenic small cell anaplastic carcinoma and staged as having regional disease all underwent combination chemotherapy consisting of CCNU, cyclophosphamide, and methotrexate. They were randomized to receive either radiotherapy to the primary tumor and regional lymph nodes (4000 rad) or extensive radiotherapy, which included the brain, adrenals, and upper retroperitoneal lymph nodes. Fifteen patients were free of disease after 18 months of chemotherapy and the treatment was discontinued. Only 3 patients subsequently relapsed. No difference was observed between the two groups of patients in median survival time, response rate, duration of response or relapse pattern, including the frequency of brain metastasis.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Brain Neoplasms / prevention & control
-
Brain Neoplasms / radiotherapy
-
Brain Neoplasms / secondary*
-
Carcinoma, Bronchogenic / drug therapy
-
Carcinoma, Bronchogenic / radiotherapy*
-
Clinical Trials as Topic
-
Cyclophosphamide / administration & dosage
-
Deglutition Disorders / chemically induced
-
Drug Therapy, Combination
-
Female
-
Hospitalization
-
Humans
-
Leukopenia / chemically induced
-
Lomustine / administration & dosage
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / radiotherapy*
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Prognosis
-
Radiotherapy / adverse effects
-
Thrombocytopenia / chemically induced
Substances
-
Antineoplastic Agents
-
Lomustine
-
Cyclophosphamide
-
Methotrexate